Gianluca Pirozzi

Best Publications

• Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

  Eric L. Simpson;Thomas Bieber;Emma Guttman-Yassky;Lisa A. Beck

  2113
  Citations

• Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

  Mario Castro;Jonathan Corren;Ian D. Pavord;Jorge Maspero

  1930
  Citations

• Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

  Lisa A. Beck;Diamant Thaçi;Jennifer D. Hamilton;Neil M. Graham

  1539
  Citations

• Dupilumab in persistent asthma with elevated eosinophil levels.

  Sally Wenzel;Linda Ford;David Pearlman;Sheldon Spector

  1501
  Citations

• Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

  Claus Bachert;Claus Bachert;Joseph K Han;Martin Desrosiers;Peter W Hellings

  1450
  Citations

• Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

  Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  1357
  Citations

• Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

  Klaus F. Rabe;Parameswaran Nair;Guy Brusselle;Jorge F. Maspero

  1152
  Citations

• Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

  Sally Wenzel;Mario Castro;Jonathan Corren;Jorge Maspero

  1086
  Citations

• Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial

  Claus Bachert;Claus Bachert;Leda Mannent;Robert M Naclerio;Joaquim Mullol

  849
  Citations

• Targeting key proximal drivers of type 2 inflammation in disease

  Namita A. Gandhi;Brandy L. Bennett;Neil M. H. Graham;Gianluca Pirozzi

  779
  Citations

• Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

  Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  719
  Citations

• Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

  Emma Guttman-Yassky;Emma Guttman-Yassky;Robert Bissonnette;Benjamin Ungar;Benjamin Ungar;Mayte Suárez-Fariñas

  661
  Citations

• Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.

  Eric L. Simpson;Amy S. Paller;Elaine C. Siegfried;Mark Boguniewicz

  528
  Citations

• Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

  M. de Bruin-Weller;D. Thaçi;C.H. Smith;K. Reich

  523
  Citations

• Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.

  Jennifer D. Hamilton;Mayte Suárez-Fariñas;Nikhil Dhingra;Irma Cardinale

  518
  Citations

• Commonality of the IL-4/IL-13 pathway in atopic diseases

  Namita A. Gandhi;Gianluca Pirozzi;Neil M. H. Graham

  501
  Citations

• Conjunctivitis in dupilumab clinical trials.

  B. Akinlade;E. Guttman-Yassky;M. de Bruin-Weller;E. L. Simpson

  423
  Citations

• Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults

  Eric L. Simpson;Thomas Bieber;Laurent Eckert;Richard Wu

  345
  Citations

• Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.

  G. Yosipovitch;M. Reaney;V. Mastey;L. Eckert

  330
  Citations

• Dupilumab Shows Long-Term Safety and Efficacy in Patients With Moderate to Severe Atopic Dermatitis Enrolled in a Phase 3 Open-Label Extension Study

  Mette Deleuran;Diamant Thaçi;Lisa A. Beck;Marjolein de Bruin-Weller

  246
  Citations